Astellas Pharma and Audax Biosciences have announced a high-stakes exclusive option and license agreement centered on DAX-044, a promising immuno-oncology candidate that could redefine the landscape of tumor-targeted therapies. This strategic partnership grants Astellas the exclusive right to develop, manufacture, and commercialize the drug, potentially signaling a new era for cytokine-based cancer treatments.
At the heart of the deal is DAX-044, an investigational antibody-cytokine fusion protein developed using Audax’s proprietary Avikine platform. Interleukin-12 (IL-12) has long been recognized for its potent ability to stimulate anti-tumor immune responses, but its clinical utility has historically been hampered by severe systemic toxicity. Audax’s platform aims to bypass these limitations by concentrating the immune-activating activity of IL-12 specifically within the tumor microenvironment. Preclinical studies have already suggested that DAX-044 possesses a best-in-class therapeutic index, marking it as a significant candidate for further development.
The financial scope of the agreement reflects the confidence Astellas has placed in the technology. Audax is set to receive $285 million in upfront and potential future option exercise payments. Furthermore, the agreement includes an additional $1.05 billion in potential development and commercial milestone payments, alongside tiered royalties, should the therapy progress through clinical milestones and regulatory hurdles.
Under the terms of the deal, Audax will retain responsibility for development through the initial Phase I clinical study, which is currently scheduled to commence in 2027. Audax has also secured an option to co-fund and co-promote the asset within its home markets of Australia and New Zealand, ensuring a continued role for the biotech firm in the therapy’s journey.
Takahiko Iwaya, Chief Strategy Officer at Astellas, expressed optimism regarding the collaboration, noting that DAX-044 aligns perfectly with the company’s commitment to addressing unmet needs in oncology. “DAX-044 is a promising investigational immuno-oncology program with a differentiated mechanism designed to selectively activate anti-tumor immune responses,” Iwaya stated. “We hope to advance this treatment option for patients with solid tumors, including cancers where effective immune stimulation remains important.”
For Audax Biosciences, the partnership acts as a major catalyst for growth. CEO Jai Rautela, PhD, highlighted the synergy between the two companies, describing Astellas as an “ideal” partner that shares the firm’s pioneering spirit. “This partnership will expedite the planned Phase I clinical evaluation of DAX-044 for the benefit of patients,” Rautela said. “This transaction demonstrates confidence in our approach to novel therapeutic development.”
As the industry watches, the transition from IND-enabling development to the anticipated 2027 clinical trials will be a critical period for both companies. If successful, DAX-044 could prove to be a landmark advancement in the effort to harness the immune system’s power against solid tumors while minimizing the collateral damage traditionally associated with cytokine therapy.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
